Trial Profile
A two arm phase I dose escalation trial of vinflunine with erlotinib or pemetrexed in refractory solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Pemetrexed (Primary) ; Vinflunine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 May 2012 Actual patient number is 41 according to ClinicalTrials.gov.
- 15 May 2012 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.